Jeroen van der Laak appointed professor of Computational Pathology
From February 1, 2022, Jeroen van der Laak was appointed full professor of computational Pathology at the Radboud UMC.
From February 1, 2022, Jeroen van der Laak was appointed full professor of computational Pathology at the Radboud UMC.
Wouter Bulten succesfully defended his PhD thesis titled 'Artificial intelligence as a digital fellow in pathology: human-machine synergy for improved prostate cancer diagnosis.' on the 28th of January.
After two years of hard work, the final results of PANDA Challenge on AI for prostate cancer grading are published!
The latest work by Natália Alves, titled “Fully Automatic Deep Learning Framework for Pancreatic Ductal Adenocarcinoma Detection on Computed Tomography”, has been published in Cancers' special issue on Pancreatic Cancer: Pathogenesis, Early Diagnosis, and Management for Improved Survival.
The European Research Council awarded Geert Litjens with a grant for his project "AIS-CaP: Interpretable Artificial Intelligence across Scales for Next-Generation Cancer Prognostics".
The Dutch Cancer Society awarded Colin Jacobs with a grant for his research project entitled "AMARA: Accurate MAlignancy Risk estimation of incidentally and screen-detected pulmonary nodules using Artificial intelligence".
The latest work by Cristina González-Gonzalo, titled “Trustworthy AI: Closing the gap between development and integration of AI systems in ophthalmic practice”, has been accepted for publication in Progress in Retinal and Eye Research (ranked #1 in Ophthalmology).
The DKF awarded the grant to CPG’s Meyke Hermsen, Dominique van Midden, and Jeroen van der Laak for their proposal to use AI for improved histopathologic kidney biopsy assessment.
Francesco Ciompi and Chella van der Post have been awarded 400,000 euros for the execution of their project aimed to develop AI solutions for improving DGC diagnostics.
In this project, we aim to maximize lung cancer screening efficiency by developing prediction models to 1) optimize screenee selection, and 2) limit unnecessary nodule work-up.